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Abstract: This study aimed to evaluate the efficacy of anaplastic lymphoma kinase (ALK)-inhibitors 
in the treatment of ALK-positive non-small cell lung cancer (NSCLC) by using a meta-analysis of 
clinical trials. We searched PubMed, EMBASE, Cochrane Library, and Clinicaltrials.gov by using 
keywords related to the topic in August 2018. The pooled effect sizes were calculated based on a 
random-effects model. We also performed subgroup meta-analysis by types of ALK inhibitors 
(crizotinib, ceritinib, and alectinib). A total of 20 clinical trials with 10 single-arm trials and 10 
double-arm trials were included in the final meta-analysis. The median overall survival (OS), 
progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), 1 year 
survival rate, and 2 year survival rate were 19.14 months, 8.47 months, 62%, 78%, 74%, and 62%, 
respectively. ALK inhibitors showed a significantly superior efficacy compared with chemotherapy 
(hazard ratio (HR) for OS, 0.83; HR for PFS, 0.43; rate difference (RD) for ORR, 0.23; and RD for 
DCR, 0.10). The current meta-analysis of clinical trials showed the significant efficacy of ALK 
inhibitors in the treatment of ALK-positive NSCLC. Further head-to-head trials are needed to 
compare their efficacy with other types of NSCLC treatment regimens. PROSPERO registration: 
CRD42018085987. 
Keywords: ALK inhibitors; non-small cell lung cancer; crizotinib; ceritinib; alectinib 
 
1. Introduction 
Non-small cell lung cancer (NSCLC) accounts for approximately 85–90% of lung cancers, which 
are the most common fatal malignancy and leading cause of cancer mortality worldwide [1,2]. It is 
reported that the median overall survival (OS) with platinum-based chemotherapy is approximately 
7.5–28.2 months among advanced NSCLC patients, and the median progression-free survival (PFS) 
is approximately 2.1–6.9 months [3]. In the last decade, the treatment of advanced NSCLC has shifted 
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into determining molecular subtypes of the disease based on oncogenic drivers, which has led to the 
introduction of several newly approved biological agents [4]. 
One of them is crizotinib, initially designed for a mesenchymal–epithelial transition factor (MET) 
inhibitor in 2007, which prompted the development of anaplastic lymphoma kinase (ALK) target 
therapy [5]. It became the first ALK inhibitor to be approved by the Food and Drug Administration 
(FDA) in 2011 for standard first-line therapy in ALK-positive NSCLC, which accounts for 
approximately 2–7% of patients diagnosed with NSCLC [6]. However, the progression of brain 
metastases and resistance were the biggest challenges during crizotinib treatment [7]. In 2014 and 
2015, next-generation ALK inhibitors such as ceritinib and alectinib were approved by the FDA for 
the treatment of ALK-positive NSCLC patients who have developed or are intolerant to crizotinib 
[8,9].  
Since the initial development of ALK inhibitors, subsequent clinical trials on the efficacy of the 
ALK inhibitors have been published [10–29]. Several systematic reviews and meta-analyses have also 
been reported [30–33]. However, Fan J et al. mainly investigated the efficacy and safety of alectinib, 
although they reported the findings of ORR and DCR for alectinhib in the ALK inhibitor-naïve or 
crizotinib-resistant patients [31]. The OS, which shows primary outcomes for clinical trials of 
oncology as well as other efficacy outcomes such as 1-year survival rate and 2 year survival rate, has 
not been investigated [31]. Although a network meta-analysis of the same research group, focusing 
on the comparative treatment effect of ALK inhibitors, reported the aggregated estimates for some 
outcomes, it included phase I or phase I/II studies that reported responses affected by dose 
differences [30]. Two publications reported the results from a qualitative review and a quantitative 
meta-analysis mainly based on the small number of four or five individual studies, respectively, from 
a search of only PubMed [32,33]. 
The current study aimed to investigate the efficacy of ALK inhibitors in patients with ALK-
positive NSCLC using a meta-analysis of clinical trials. 
2. Results 
2.1. Selection of Relevant Studies 
By the initial search of four databases (Pubmed, Embase, Cochrane Library, and 
Clinicaltrials.gov) and hand-searching relevant bibliographies, we identified 2667 articles (Figure 1). 
After excluding 336 duplicated articles, two authors independently reviewed and excluded 2223 
articles that did not satisfy the selection criteria based on each article’s title and abstract. Among 
them, 88 articles were excluded after reviewing the full text of the remaining 108 articles. The reasons 
for exclusion were not relevant (n = 50), retrospective chart reviews (n = 7), no specific data for 
outcome measures (n = 7), no sufficient ALK-positive NSCLC (n = 3), data overlapping (n = 16), and 
no available data on results (n = 5). A total of 20 clinical trials were included in the final analysis with 
18 studies [10–24,26,28,29] in English and two studies [25,27] in Chinese. 
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Figure 1. Flow diagram for selection of relevant clinical trials. 
2.2. General Characteristics of Studies  
The general characteristics of the included studies are shown in Table 1. Except for 13 global 
multicenter trials [10,11,14,16–24,29], the seven remaining studies were conducted in China [12,25–27] and 
Japan [13,15,28]. Four studies [10,12,21,26] (1344 patients), three studies [11,16,28] (406 patients), and 
three studies [14,15,23] (243 patients) used a single arm design for the efficacy of crizotinib, ceritinib, 
and alectinib, respectively. Five studies [18–20,25,27] (967 patients), two studies [22,24] (607 patients), 
one study [29] (72 patients), and two studies [13,17] (510 patients) investigated the efficacy of 
crizotinib versus chemotherapy, ceritinib versus chemotherapy, alectinib versus chemotherapy, and 
alectinib versus crizotinib, respectively.  
2.3. Risk of Bias for Randomized, Double-Blind, Placebo-Controlled Trials 
Table 2 shows the assessment of the risk of bias for randomized, double-blind, placebo-
controlled trials. Most of the trials demonstrated a low risk of bias in less than five out of seven items, 
except for one trial with low risk of bias in six items [18].  
Begg’s funnel plot and Egger’s test showed no evidence for publication bias (p > 0.05 for PFS, 
overall response rate (ORR), disease control rate (DCR), and 1 year survival rate; Figure 2). 
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Table 1. General characteristics of clinical trials included in the final analysis. 
Study Enrollment Period Regimen No. pts 
OS (95% CI) 
(Months) 
PFS (95% CI) 
(Months) 
ORR 
(%) 
DCR 
(%) 
1-Year 
Survival 
Rate 
2-Year 
Survival Rate 
Single-arm study 
Camidge 2012 [10] 
(PROFILE 1001) 
08/2008-06/2011 (US, 
Australia, South 
Korea) 
Crizotinib 143 - 9.7 (7.7–12.8) 60.8 82.5 74.8 - 
Cui 2015 [12] 
06/2013-10/2014 
(China) 
Crizotinib 67 - 10.3 (8.6–12.0) 52.2 64.2 77.6 - 
Yang 2015 [26] 
12/2010-08/2014 
(China) 
Crizotinib 22 
46 
- 
13.8 (7.6–19.9) 
7.0 (3.8–10.2) 
81.8 
69.6 
- - 
65.0 
50.0 
Crino 2016 [11] 
(ASCEND-2) 
12/2012-09/2013 (51 
global sites) 
Ceritinib 140 15.6 (13.6–24.2) 5.8 (5.4–7.6) 38.6 77.1 63.8 - 
Kim 2016 [16] (ASCEND-
1) 
01/2011-07/2013 (11 
countries) Ceritinib 
83 
163 - 
- 
6.9 (5.6–8.7) 
72 
56 - 
83 
67 - 
Shaw 2016 [23] 
(NCT01871805) 
09/2013-08/2014 (US, 
Canada) 
Alectinib 87 - 8.1 (6.2–12.6) 52.9 66.7 71 - 
Iwana 2017 [15] 
09/2014-12/2015 
(Japan) 
Alectinib 18 - 10.1 (7.1–17.8) 72.2 77.8 - - 
Hida 2018 [28] 
(ASCEND-9) 
08/2015-03/2017 
(Japan) 
Ceritinib 20 - 3.7 (1.9–5.3) 25 - - - 
NCT00932451 [21] 
(PROFILE 1005) 
01/2010-03/2015 (21 
countries) 
Crizotinib 
908 
158 
21.8 (19.4–24.0) 
16.9 (13.4–21.5) 
8.4 (7.1–9.7) 
6.9 (5.6–9.4) 
54.1 
40.5 
70.8 
61.4 
66.5 
62.4 
- 
NCT01801111 [14] 
06/2013-10/2014 (16 
countries) 
Alectinib 138 - 9.1 (7.4–11.2) 47.8 68.8 - - 
Double-arm study 
Wu 2015 [25] 
06/2010-11/2014 
(China) 
Crizotinib vs 
Pemetrexed/docetaxel/
gemcitabine/paclitaxel 
+ platinum 
21 
21 
- - 
61.9 
28.6 
- - - 
Zhao 2015 [27] 
01/2012-12/2013 
(China) 
Crizotinib vs 
Dexamethasone + 
docetaxel 
14 
14 
- - 
64.3 
21.4 
- - - 
Hida 2017 [13] 
(J-ALEX) 
11/2014-08/2015 
(Japan) 
Alectinib vs Crizotinib 
103 
104 
- 
- 
10.2 (8.2–12.0) 
85 
70 
98.1 
88.5 
- - 
Peters 2017 [17] (ALEX) 
08/2014-01/2016 (98 
global sites) 
Alectinib vs Crizotinib 
152 
151 
- 
- 
10.4 (7.7–14.6) 
82.9 
75.5 
- 
84.3 
82.5 
- 
Shaw 2017 [22] 
(ASCEND-5) 
06/2013–11/2015 (20 
countries) 
Ceritinib vs 
Pemetrexed/docetaxel 
115 
116 
18.1 (13.4–23.9) 
20.1 (11.9–25.1) 
5.4 (4.1–6.9) 
1.6 (1.4–2.8) 
39.1 
6.9 
76.5 
36.3 
- - 
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Study Enrollment Period Regimen No. pts OS (95% CI) 
(Months) 
PFS (95% CI) 
(Months) 
ORR 
(%) 
DCR 
(%) 
1-Year 
Survival 
Rate 
2-Year 
Survival Rate 
Soria 2017 [24] (ASCEND-
4) 
08/2013–05/2015 (28 
countries) 
Ceritinib vs 
Cisplatin/carboplatin 
189 
187 
- 
16.6 (12.6–27.2) 
8.1 (5.8–11.1) 
72.5 
26.7 
- - 
70.6 
58.2 
NCT00932893 [18] 
(PROFILE 1007) 
09/2009–03/2012 (22 
countries) 
Crizotinib vs 
Pemetrexed/docetaxel 
173 
174 
21.7 (18.9–30.5) 
21.9 (16.8–26.0) 
7.7 (6.0–8.8) 
3.0 (2.6–4.3) 
65.3 
19.5 
64.2 
38.5 
70.4 
66.7 
- 
NCT01154140 [19] 
(PROFILE 1014) 
01/2011–11/2013 (31 
countries) 
Crizotinib vs 
Pemetrexed + 
cisplatin/carboplatin 
172 
171 
- 10.9 (8.3–13.9) 
7.0 (6.8–8.2) 
74.4 
45.0 
78.5 
68.4 
83.5 
78.4 
- 
NCT01639001 [20] 
09/2012–06/2015 (5 
Asia countries) 
Crizotinib vs 
Pemetrexed + 
cisplatin/carboplatin 
104 
103 
- 
11.1 (8.3–12.6) 
6.8 (5.7–7.0) 
87.5 
45.6 
82.7 
73.8 
79.3 
79.5 
- 
NCT02604342 [29] 
11/2015–01/2017 
(15 countries) 
Alectinib vs 
Pemetrexed/docetaxel 
72 
35 
- 
- 
9.6 (6.9–12.2) 
1.4 (1.3–1.6) 
37.5 
2.9 
80.6 
28.6 
- 
- 
- 
- 
Table 2. Summary of risk of bias assessment for randomized, double-blind, placebo-controlled trials (n = 10). 
Study 
Random Sequence 
Generation 
Allocation 
Concealment 
Blinding of 
Participants and 
Personnel 
Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective 
Reporting Other Bias 
No. of Low Risk 
of Bias 
Wu 2015 [25] Unclear risk Unclear risk Unclear risk Unclear risk Low risk Unclear risk Low risk 2 
Zhao 2015 [27] Unclear risk Unclear risk Unclear risk Unclear risk Low risk Unclear risk Low risk 2 
Hida 2017 [13] 
(J-ALEX) 
Low risk Low risk Unclear risk Low risk Unclear risk Unclear risk Low risk 4 
Peters 2017 [17] (ALEX) Low risk Low risk Unclear risk Low risk Unclear risk Unclear risk Low risk 4 
Shaw 2017 [22] 
(ASCEND-5) 
Low risk Low risk Unclear risk Low risk Unclear risk Unclear risk Low risk 4 
Soria 2017 [24] 
(ASCEND-4) 
Low risk Low risk Unclear risk Low risk Unclear risk Unclear risk Low risk 4 
NCT00932893 [18] 
(PROFILE 1007) 
Low risk Low risk Unclear risk Low risk Low risk Low risk Low risk 6 
NCT01154140 [19] 
(PROFILE 1014) 
Low risk Low risk Unclear risk Low risk Unclear risk Unclear risk Low risk 4 
NCT01639001 [20] Low risk Low risk Unclear risk Low risk Unclear risk Unclear risk Low risk 4 
NCT02604342 [29] Low risk Low risk Unclear risk Low risk Unclear risk Unclear risk Low risk 4 
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Figure 2. Begg’s funnel plots and Egger’s test for publication bias by different outcomes. (A): PFS, 
progression-free survival, (B) ORR, overall response rate, (C) DCR, disease control rate, (D) 1-year 
survival rate; SE, standard error. 
2.4. Efficacy of ALK Inhibitors in Patients with ALK-Positive NSCLC by Type of Outcomes and Type of 
ALK Inhibitors 
Table 3 shows the efficacy of ALK inhibitors in patients with ALK-positive NSCLC in the 
subgroup meta-analysis type of ALK inhibitors for each outcome in single-arm or double-arm trials. 
Overall, ceritinib showed shorter OS and PFS and lower ORR and DCR, compared with crizotinib 
and alectinib.  
In the meta-analysis of all the included studies, the median OS was 19.14 months (95% 
confidence interval (CI), 16.42–21.85; I2 = 51%; n = 5), and the median PFS was 8.47 months (95% CI, 
7.43–9.52; I2 = 80%; n = 20; Figure 3A). The pooled ORR, DCR, 1-year survival rate, and 2-year survival 
rates were 62% (95% CI, 56–68; I2 = 93%; n = 25; Figure 3B), 78% (95% CI, 71–84; I2 = 95%; n = 16), 74% 
(95% CI, 70–79; I2 = 82%; n = 13), and 62% (95% CI, 49–76; n = 3), respectively.  
Table 3. Efficacy of ALK inhibitors in patients with ALK-positive non-small cell lung cancer by type 
of ALK inhibitors for each outcome. 
Outcome No. of Groups Period/Rate (95% CI) I2 (%) 
Time period (months)    
OS [11,18,21,22] 5 19.14 (16.42–21.85) 50.5 
Crizotinib [18,21] 3 20.22 (16.94–23.50) 54.3 
Ceritinib [11,22] 2 16.86 (13.13–20.59) 0.0 
PFS (months) [10–24,26,28,29] 20 8.47 (7.43–9.52) 80.1 
Crizotinib [10,12,13,17–21,26]  11 9.27 (8.28–10.26) 56.1 
Ceritinib [11,16,22,24,28] 5 5.92 (4.36–7.48) 75.6 
Alectinib [14,15,23,29] 4 9.12 (7.77–10.46) 0.0 
Rate (%)    
ORR [10–29] 25 62 (56–68) 93.4 
Crizotinib [10,12,13,17–21,25–27] 13 66 (58–74) 92.2 
Ceritinib [11,16,22,24,28] 6 52 (38–66) 93.3 
Alectinib [13–15,17,23,29] 6 63 (46–80) 95.4 
DCR [10–15,18–23,25,28,29] [10–15,18–23,25,28,29] 16 78 (71–84) 94.8 
Crizotinib [10,12,13,18–21,25] 8 78 (71–85) 90.9 
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Outcome No. of Groups Period/Rate (95% CI) I2 (%) 
Ceritinib [11,22,28]  3 76 (71–81) 0.0 
Alectinib [13–15,23,29] 5 79 (63–95) 95.4 
1-year survival rate [10–12,16–21,23] 13 74 (70–79) 85.3 
Crizotinib [10,12,17–21] 8 75 (69–81) 86.7 
Ceritinib [11,16] 3 71 (60–83) 85.0 
Alectinib [17,23] 2 81 (76–86) 0.0 
2-year survival rate [24,26] 3 62 (49–76) 69.0 
Crizotinib [26] 2 55 (43–66) 0.0 
Ceritinib [24] 1 70 (64–76) NA 
OS, overall survival; PFS, progression-free survival; ORR, overall response rate; DCR, disease control 
rate; 95% CI, 95% confidence interval; NA, not applicable. 
Figure 3. Efficacy of ALK inhibitors in treatment of ALK-positive non-small cell lung cancer (NSCLC) 
by type of outcome and type of ALK inhibitors. (A) PFS, progression-free survival (months), (B) ORR, 
overall response rate (%). 
2.5. Efficacy of ALK Inhibitors Compared with Chemotherapy in Patients with ALK-Positive NSCLC by 
Type of Outcomes and Type of ALK Inhibitors 
Shown in Table 4, ALK inhibitors showed superior efficacy in the treatment of ALK-positive 
NSCLC compared with chemotherapy in OS (hazard ratio (HR), 0.83; 95% CI, 0.72–0.97; I2 = 0%; n = 5), 
PFS (HR, 0.43; 95% CI, 0.35–0.54; I2 = 65%; n = 6), ORR (rate difference (RD), 23%; 95% CI, 17–29, I2 = 
53%; n = 8), and DCR (RD, 10%; 95% CI, 4–16, I2 = 45%; n = 6). 
In the subgroup meta-analysis by type of ALK inhibitors, similar findings were observed in PFS 
(HR, 0.45; 95% CI, 0.38–0.54; n = 3 for crizotinib vs. chemotherapy; HR, 0.52; 95% CI, 0.43–0.64; n = 2 
for ceritinib vs. chemotherapy; and HR, 0.15; 95% CI, 0.08–0.29; n = 1 for alectinib vs. chemotherapy),  
ORR (RD, 19%; 95% CI, 12–26; n = 5 for crizotinib vs. chemotherapy; RD, 28%; 95% CI, 16–40; n = 2 for 
ceritinib vs. chemotherapy; and RD, 29%; 95% CI, 18–40; n = 1 for alectinib vs. chemotherapy), and 
DCR (RD, 6%; 95% CI, 1–11; n = 4 for crizotinib vs. chemotherapy and RD, 18%; 95% CI, 8–28; n = 1 
for ceritinib vs. chemotherapy). However, crizotinib and ceritinib did not significantly improve the 
OS (HR, 0.83; 95% CI, 0.69–1.00, n = 3 and HR, 0.85; 95% CI, 0.62–1.16, n = 2, respectively). Also, 
crizotinib and ceritinib showed no significant efficacy in 1 year survival rate and 2 year survival rate, 
respectively. 
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Further, the pooled risk of disease progression in two studies was significantly lower in patients 
treated with alectinib than those treated with crizotinib (HR for PFS, 0.47; 95% CI, 0.35–0.63; I2 = 0%; 
Figure 4A). Meanwhile, there was no difference in the efficacy of alectinib versus crizotinib in ORR 
(Figure 4B). 
Table 4. Efficacy of ALK inhibitors compared with chemotherapy in patients with ALK-positive non-
small cell lung cancer by type of ALK inhibitors for each outcome. 
Outcome No of Groups Effect size  
(95% CI) 
I2 (%) 
Effect size: Hazard ratio 
OS [18–20,22,24] 5 0.83 (0.72–0.97) 0.0 
Crizotinib [18–20] 3 0.83 (0.69–1.00) 0.0 
Ceritinib [22,24] 2 0.85 (0.62–1.16) 19.1 
PFS [18–20,22,24,29] 6 0.43 (0.35–0.54) 64.7 
Crizotinib [18–20] 3 0.45 (0.38–0.54) 0.0 
Ceritinib [22,24] 2 0.52 (0.43–0.64) 0.0 
Alectinib [29] 1 0.15 (0.08–0.29) NA 
Effect size: Rate difference (%) 
ORR [18–20,22,24,25,27,29] 8 23 (17–29) 52.7 
Crizotinib [18–20,25,27] 5 19 (12–26) 36.5 
Ceritinib [22,24] 2 28 (16–40) 65.4 
Alectinib [29] 1 29 (18–40) NA 
DCR [18–20,22,25,29] 6 10 (4–16) 44.8 
Crizotinib [18–20,25] 4 6 (1–11) 0.0 
Ceritinib [22] 1 18 (08–28) NA 
Alectinib [29] 1 18 (06–30) NA 
1-year survival rate [18–20]    
Crizotinib [18–20] 3 1 (−4, 6) 0.0 
2-year survival rate [22]    
Ceritinib [22] 1 5 (−3, 13) NA 
OS, overall survival; PFS, progression-free survival; ORR, overall response rate; DCR, disease control 
rate; 95% CI, 95% confidence interval; NA, not applicable. 
 
Figure 4. Efficacy of alectinib versus crizotinib in treatment of ALK-positive NSCLC by type of 
outcome. (A) progression-free survival, (B) overall survival rate; HR, hazard ratio, RD, rate difference, 
95% CI, 95% confidence interval. 
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3. Discussion 
3.1. Summary of Findings 
In the current meta-analysis of clinical trials, we demonstrated that the median OS, PFS, ORR, 
DCR, 1 year survival rate, and 2 year survival rate for ALK inhibitors including crizotinib, ceritinib, 
and alectinib in the treatment of ALK-positive NSCLC was 19.14 months, 8.47 months, 62%, 78%, 
74%, and 62%, respectively. In the subgroup analysis by type of ALK inhibitor, overall ceritinib 
showed shorter OS and PFS and lower ORR and DCR compared with crizotinib and alectinib. As 
compared with chemotherapy, ALK inhibitors showed superior efficacy in the treatment of ALK-
positive NSCLC.  
3.2. Comparison with Previous Studies 
Our findings are consistent with those from retrospective chart review studies. El. Din et al. 
reported that crizotinib showed a 1 year survival rate of 71.2% and an objective response rate of 70.9% 
[34]. Bendaly et al. reported that the ORR for ceritinib was 69% and median PFS was 12.9 months [6]. 
In a large, multi-country medical chart review (n = 1471) with seven countries, there was a significant 
improvement in complete response (odds ratio (OR), 2.65; 95% CI, 1.69–4.15) and a significant 
reduction in recurrence/progression (OR, 0.38; 95% CI, 0.24–0.59) [35].  
Recently, a network meta-analysis reported higher response (ORR, 64%; 95% CI, 59-69 and DCR, 
85%; 82–88) and PFS (9.2 months; 95% CI, 8.18–10.22 months) than those in our study [30]. In 
comparison with chemotherapy, ALK inhibitors showed a significantly longer PFS with the pooled 
HR (95% CIs) of 0.71 (0.66–0.76) for crizotinib, 0.75 (0.69–0.83) for ceritinib, and 0.50 (0.43–0.58) for 
alectinib [30]. Especially, alectinib was found to decrease the risk of ALK-positive NSCLC progression 
(HR, 0.70; 95% CI, 0.61–0.80) compared with crizotinib in the network meta-analysis [30]. 
However, in the recent meta-analysis of five randomized trials, ALK-targeted therapy 
performed better in PFS (HR = 0.48; 95% CI, 0.42–0.55), but not for OS (HR, 0.88, 95% CI, 0.72–1.07) 
[32], while another meta-analysis of four trials reported superior therapeutic outcomes regarding the 
increased 1 year and 2 year OS, PFS, and ORR, compared to chemotherapy [33].  
3.3. Possible Mechanisms  
There are several mechanisms regarding the therapeutic efficacy of ALK inhibitors in the treatment 
of ALK-positive NSCLC. In ALK-positive NSCLC, ALK- echinoderm microtubule-associated protein-
like 4 (EML4) fusion protein activates the RAS/mitogen-activated protein kinase (MAPK), 
phosphatidylinositol 3-kinase (PI3K)/AKT, and janus kinase (JAK)/signal transducer, and the activator 
of transcription 3 (STAT) pathways are reported to play the important role in the development of 
NSCLC [5,36]. In the meantime, it has been shown that ALK inhibitors can bind the ALK protein to 
prevent the activation of NSCLC pathways [5,36]. 
Regarding the resistance to crizotinib, several biological mechanisms have been proposed [37]. 
Resistance may arise through the pathway of selective copy number gain or gene amplification (ALK-
dependent) [37,38]. However, about 70% of crizotinib resistance is attributable to the abnormal 
activation of alternative signaling pathways involving ALK-independent growth, not to identifiable 
secondary resistance mutations or ALK copy number alterations [39,40]. Even though crizotinib 
significantly improved the treatment response compared with conventional chemotherapy, the 
disease progression in the central nervous system has still frequently occurred [41]. Thus, second-
generation ALK inhibitors including ceritinib and alectinib with higher selectivity were designed to 
overcome resistance issues related to crizotinib and improve the activity of treatment therapy in the 
central nervous system [42]. 
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3.4. Strengths and Limitations 
To the best of our knowledge, this is the first meta-analysis to investigate the overall profile of 
ALK inhibitors’ efficacy in the treatment of ALK-positive NSCLC. We also estimated the efficacy of 
crizotinib, ceritinib, and alectinib compared with chemotherapy, respectively.  
However, there are several limitations in the current study. First, although we found that ALK 
inhibitors improved PFS in considerable trials, OS was not sufficiently evaluated due to a relatively 
small number of trials. As a surrogate, PFS can be evaluated faster, with fewer patients. However, OS 
is still considered to be the gold standard in clinical trials of oncology drugs [43]. Second, substantial 
heterogeneity was observed in the meta-analysis of single-arm studies for all the outcomes and 
double-arm studies for PFS, ORR, and DCR outcomes (I2 > 50%). Last, due to a small number of trials, 
we were unable to conduct the head-to-head comparisons among different types of ALK inhibitors.  
4. Materials and Methods  
The protocol for this systematic review and meta-analysis was registered with the International 
Prospective Register of Systematic Reviews (PROSPERO registration number: CRD 42018085987). 
4.1. Literature Search 
We searched Pubmed, EMBASE, Cochrane library, and Clinicaltrials.gov databases from their 
inception until August 2018, limiting it to human subjects and clinical trials. The keywords for the 
literature search were as follows: ‘crizotinib’, ‘ceritinib’, ‘alectinib’, and ‘ALK inhibitor’ for 
intervention factors; ‘non-small cell lung cancer’ for outcome factor; ‘clinical trial’, ‘randomized 
controlled trial’ for study type. The bibliographies of relevant articles were also reviewed to identify 
additional studies. The format (abstract or full text) and language of publications were not restricted. 
4.2. Study Selection and Eligibility Criteria 
We included clinical trials that investigated the efficacy of three ALK inhibitors (crizotinib 250 
mg bid, ceritinib 750 mg·qd, or alectinib 300/600 mg·bid) in ALK-positive NSCLC patients and 
reported findings on at least one of the following outcomes, i.e., OS (time from randomization to 
death), PFS (time from randomization to disease progression), ORR (complete response plus partial 
response), DCR (complete response plus partial response and stable disease), 1 year survival rate, 
and 2 year survival rate. The longer survival time in OS and PFS, or higher percentage of ORR, DCR, 
1 year survival rate and 2 year survival rate a treatment has, the higher its efficacy. For studies using 
the same data, completely duplicated records were excluded, while partially duplicated records were 
combined to obtain the full information. Based on the eligibility criteria, two investigators (Hoang 
and Myung) independently selected studies to be included in the analysis. 
4.3. Statistical Analyses 
We used OS, PFS, ORR, DCR, 1 year survival rate, and 2 year survival rate with 95% CIs from 
individual studies to calculate the pooled effect time/ effect rate. For studies using the comparison 
group, we calculated a pooled HR for OS, PFS and a RD for ORR, DCR, 1 year survival rate, and 2 
year survival rate between the two groups. 
In order to measure heterogeneity across studies, we used Higgins I2, which estimates the 
percentage of total variation across studies. Negative values of I2 are set to zero; I2 ranges between 
0% (no observed heterogeneity) and 100% (maximal heterogeneity) [39]. A random-effects model was 
used to calculate a pooled effect size [40]. 
Publication bias where 10 or more studies were available was examined by using Begg’s funnel 
plot and Egger’s test [41,44]. We also estimated the risk of bias for eligible studies based on the 
Cochrane Risk of Bias Tool [39]. We used the Stata SE version 14.0 software (StataCorp, College 
Station, Texas, USA) for the statistical analysis. 
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5. Conclusions 
In conclusion, the current meta-analysis of clinical trials suggests the superior efficacy of ALK 
inhibitors including crizotinib, ceritinib, and alectinib in the treatment of ALK-positive NSCLC, 
compared with chemotherapy. Further randomized controlled trials are needed to evaluate the 
efficacy of different types of ALK inhibitors in head-to-head trials and the efficacy of those compared 
with other types of NSCLC treatment regimens. 
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